Brief: Akeso Announced NDA Acceptance Of IL-12/IL-23 Monoclonal Antibody Ebdarokimab For Moderate-To-Severe Plaque Psoriasis By China NMPA
24/08/2023 13:12
Aug 24 (Reuters) - Akeso Inc 9926.HK :
* AKESO ANNOUNCED NDA ACCEPTANCE OF IL-12/LL-23 MONOCLONAL
ANTIBODY EBDAROKIMAB FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS BY
CHINA NMPA
Source text for Eikon: ID:nPn45l65Ma
Further company coverage: 9926.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals